News | November 04, 2023
Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr
Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023
This product will be manufactured at Lupin's Nagpur facility in India
Lyka Labs has reported total income of Rs. 28.23 crores during the period ended September 30, 2023
Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023
The company has posted net profit of Rs.978.93 crores for the 6 months period ended September 30, 2023
Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023
Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
Subscribe To Our Newsletter & Stay Updated
